Welcome to the e-CCO Library!

P398: Long term efficacy and safety of ABP 501 adalimumab biosimilar in inflammatory bowel diseases: preliminary results from the ADASWITCH study
Year: 2022
Source: ECCO'22
Authors: Cingolani, A.(1);Felice, C.(2);Lombardi, G.(3);Onidi, F.M.(4);Checchin, D.(5);Colucci, R.(6);Grossi, L.(7);Ferronato, A.(8);Rocchi, C.(9);Ascolani, M.(10);Binaghi, L.(4);Dore, M.F.(4);Fanini, L.(11);Bulajic, M.(9);MocciMD FRCP, G.(4);
Created: Friday, 11 February 2022, 3:52 PM
P398: The costs of care for patients with ulcerative colitis: effect of adalimumab on health care resources utilisation in clinical practice from INSPIRADA
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

S. Travis*1, B. Feagan2, L. Peyrin-Biroulet3, R. Panaccione4, S. Danese5, A. Lazar6, A. Robinson7, J. Petersson7, M. Bereswill6, M. Skup7, N. Chen7, S. Wang7, R. Thakkar7, J. Chao7

Created: Friday, 22 February 2019, 9:49 AM
P399 Endoscopic and histologic outcome in tofacitinib treated refractory moderate-to-severe ulcerative colitis: A prospective real-life cohort
Year: 2020
Source:

ECCO'20 Vienna

Authors:

B. Verstockt1, A. Outtier1, J. Lefrère1, J. Sabino1, S. Vermeire1, G. De Hertogh2, M. Ferrante2

Created: Thursday, 30 January 2020, 10:12 AM
P399: Adverse events associated with azathioprine treatment in Korean pediatric inflammatory bowel disease patients
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Kim M.

Created: Wednesday, 20 February 2019, 10:36 AM
P399: C-Reactive Protein Values After Surgery for Inflammatory Bowel Disease: Is It Still A Good Marker For Intra-Abdominal Complication? A Retrospective Cohort Study of 347 procedures.
Year: 2022
Source: ECCO'22
Authors: Gaspard, B.(1);Alexandre, C.(1);thibault, V.(1);Lauren, O.(2);Clotilde, D.(1);Najim, C.(1);yann, P.(1);Lefevre, J.(1);
Created: Friday, 11 February 2022, 3:52 PM
P399: Cost-effectiveness of utilising proactive Infliximab therapeutic drug monitoring for inflammatory bowel disease in routine clinical practice
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

J. Steen*1, M. McCormack2, C. McShane1, M. Healy2, V. Crowley2, U. Kennedy1, O. Hayes1, C. Dunne1, K. Hartery1, S. McKiernan1, F. MacCarthy1, D. Kevans1

Created: Friday, 22 February 2019, 9:41 AM
P399: Detection of iron restricted erythropoiesis in patients with IBD: How can we disentangle effects of inflammation?
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Aksan, A.(1,2,3)*;Mangold, C.(4);Stötzel, J.(1,3);Tessmer, L.(3,5);Schröder, O.(3,5);Stein, J.M.(3,5,6);
Created: Friday, 14 July 2023, 11:05 AM
P399: Higher anti-tumour necrosis factor-alpha drug levels are associated with improved radiological outcomes in patients with perianal fistulising Crohn’s disease: A retrospective multi-centre study
Year: 2021
Source: ECCO'21 Virtual
Authors: De Gregorio, M.(1,2);Lee, T.(1);Krishnaprasad, K.(1,3);Amos, G.(4,5);An, Y.K.(4,6);Bastian-Jordan, M.(4,5);Begun, J.(6,7);Borok, N.(8,9);Brown, D.J.M.(10);Cheung, W.(11);Connor, S.(12,13,14);Gerstenmaier, J.(11);Gilbert, L.E.(15);Gilmore, R.(16);Gu, B.(12,14,17);Kutaiba, N.(18,19);Lee, A.(20,21);Mahy, G.(22);Srinivasan, A.(16,23,24);Thin, L.(25,26);Thompson, A.(1,2);Welman, C.J.(27);Yong, E.X.(28);De Cruz, P.(2,16);van Langenberg, D.(23,24);Sparrow co-lead senior author, M.(15,24);Ding, N.S.(1,2);
Created: Wednesday, 2 June 2021, 4:12 PM
P399: Testing patients initiating anti-TNFα agents for mycobacterial infection using interferon-gamma release assays (IGRA): The combined experience of a large dermatology and Inflammatory Bowel Disease service
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

S. Rajagopal*1, K. Greveson2, S. McBride3, A. Waite3, M. Lipman4, C. Murray2

Created: Friday, 22 February 2019, 9:49 AM
P399: Vedolizumab therapy results in reduced hospitalisation and steroid use over 1-year: Results from the Scottish vedolizumab consortium
Year: 2018
Source: ECCO '18 Vienna
Authors:

N. Plevris1*, C.S. Chuah1, R. Allen2, P. Baker2, P. Brennan3, A. Churchhouse1, E. Donoghue4, D. Gaya2, H. Jafferbhoy5, P. Jenkinson1, G. Jones1, J. Macdonald2, M. MacMaster2, C. Mowat3, G. Naismith6, L. Potts7, E. Saffouri2, J.P. Seenan2, A. Sengupta5, P. Shasi3, J. Todd3, J. Veryan2, A. Watson8, D. Watts4, I. Arnott1, C. Lees1, M. Groome3 M. Calvo1*, I. Alonso2, K. Villa1,3, V. Matallana1, Y. González Lama1, M.I. Vera1, A. Sanchez Movilla2, P. Calvo2, A. Royuela4, L. Abreu1

Created: Thursday, 21 February 2019, 9:14 AM
P400 Understanding the impact of TNF-α antagonists on the severity of non-melanoma skin cancer in inflammatory bowel disease and the consequences for therapy
Year: 2020
Source:

ECCO'20 Vienna

Authors:

C. Townsend, R. Khanna, A.S. Wilson

Created: Thursday, 30 January 2020, 10:12 AM
P400: Anti-TNF treatment for extraintestinal manifestations of inflammatory bowel disease in the Swiss IBD Cohort Study
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

T. Greuter*1, L. Biedermann1, G. Rogler1, E. Safroneeva2, A. Schoepfer3, S. Vavricka1, 4

Created: Friday, 22 February 2019, 9:49 AM
P400: Bowel ultrasonography, a non invasive easy-to-use method to predict the need to step-up therapy in inflammatory bowel disease patients
Year: 2021
Source: ECCO'21 Virtual
Authors: Les, A.(1);Iacob, R.(1);Cotruta, B.(1);Saizu, R.(1);Gheorghe, L.(1);Gheorghe, C.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P400: Discordance in patient and physician perspectives and priorities in communication and management of ulcerative colitis: results of the European ulcerative colitis narrative survey
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

L. Peyrin-Biroulet1, A. Hart2, C. Kayhan3, A. Armuzzi4, S. Schreiber*5

Created: Friday, 22 February 2019, 9:41 AM
P400: Evolution of clinical and pharmacological parameters after switching from intra-venous to subcutaneous infliximab in patients with inflammatory bowel disease: the REMSWITCH study
Year: 2022
Source: ECCO'22
Authors: Buisson, A.(1);Nachury, M.(2);Reymond, M.(1);Yzet, C.(3);Wils, P.(2);Payen, L.(1);Manlay, L.(1);Pereira, B.(4);Fumery, M.(3);
Created: Friday, 11 February 2022, 3:52 PM
P400: Identifying Nutritional targets in Crohn's disease: INTICO1: a time-limited trial of exclusive enteral nutrition during adult CD remission
Year: 2023
Source: ECCO’23 Copenhagen
Authors: McDonnell, M.(1,2)*;Westoby, C.(3);Sartain , S.(1);Giannasca, P.(4);Corthésy, J.(5);Grzywinski, Y.(6);Frézal, A.(5);Capt, P.(5);Cummings, F.(1);Wootton, S.(7);
Created: Friday, 14 July 2023, 11:05 AM
P400: Risk-adjusted use of thiopurines prevented surgical recurrence in patients with Crohn's disease after intestinal resection
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Guo J.1, Mao R.1, Luo X.1, Ben Horin S.1,2, Chen M.*3

Created: Wednesday, 20 February 2019, 10:36 AM
P401 Sarcopenia in children and young adults with primary sclerosing cholangitis and IBD
Year: 2020
Source:

ECCO'20 Vienna

Authors:

E. Shteyer1, R. Cytter-Kuint2, L. Winberg2

Created: Thursday, 30 January 2020, 10:12 AM
P401: Anti-TNF treatments in Crohn's disease and improvement in work productivity and quality of life: an observational study from Turkey
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Törüner M.*1, Başaranoğlu M.2, Atuğ Ö.3, Şentürk Ö.4, Akyüz F.5, Ünsal B.6, Över Hamzaoğlu H.7, Tekin F.8, Sezgin O.9, Akpınar H.10, Çelik A.F.11, Tezel A.12, Göktürk H.S.13, Kav T.14

Created: Wednesday, 20 February 2019, 10:36 AM
P401: Association between induction vedolizumab drug levels and therapy outcome in inflammatory bowel disease
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

J. O'Connell1, M. S. Ismail2, M. McCormack3, P. McDonagh1, R. Argue4, N. Breslin2,5, V. Crowley3, G. Cullen5,6, G. A. Doherty5,6, C. Dunne1,5, K. Hartery1,5, F. MacCarthy5,7, S. McKiernan1,5, H. Mulcahy5,6, A. O'Connor2,5, C. O'Morain8, B. Ryan2,5, J. Sheridan5,6, M. Healy3, D. McNamara2,5, D. Kevans1,5

Created: Friday, 22 February 2019, 9:41 AM